Application of DNA methylation biomarkers for endometrial cancer management

Shi Wen Jiang, Jinping Li, Karl Podratz, Sean Christopher Dowdy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It has become clear that aberrant gene expression, via alterations in promoter methylation or histone acetylation, is a contributing factor for carcinogenesis, perhaps as important as genetic mutation. This is particularly evident in endometrial cancer, in which multiple genes are silenced through hypermethylation. In this review, we discuss the field of epigenetics and relevant techniques to characterize methylation and acetylation alterations. The CpG island methylator phenotype, epimutations and the effects of aging on methylation are also discussed. In endometrial cancer there is evidence that hypermethylation of relevant genes can be reversed using epigenetic inhibitors, resulting in re-expression of silenced genes. Preliminary data also suggest that a panel of methylation biomarkers could be useful for diagnosis and even screening in selected populations at high risk. This disease is particularly well suited for such a strategy given that the endometrium is readily accessible for testing and endometrial cancer precursors are well defined.

Original languageEnglish (US)
Pages (from-to)607-616
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume8
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

DNA Methylation
Endometrial Neoplasms
Methylation
Biomarkers
Acetylation
Epigenomics
Gene Expression
CpG Islands
Endometrium
Histones
Genes
Carcinogenesis
Phenotype
Mutation

Keywords

  • Biomarker
  • Cancer diagnosis
  • Cancer treatment
  • DNA methylation
  • Endometrial cancer
  • Epigenetics
  • Intravaginal tampons

ASJC Scopus subject areas

  • Genetics

Cite this

Application of DNA methylation biomarkers for endometrial cancer management. / Jiang, Shi Wen; Li, Jinping; Podratz, Karl; Dowdy, Sean Christopher.

In: Expert Review of Molecular Diagnostics, Vol. 8, No. 5, 09.2008, p. 607-616.

Research output: Contribution to journalArticle

@article{4ef7a7d079604443bf5dd19fe46e7d31,
title = "Application of DNA methylation biomarkers for endometrial cancer management",
abstract = "It has become clear that aberrant gene expression, via alterations in promoter methylation or histone acetylation, is a contributing factor for carcinogenesis, perhaps as important as genetic mutation. This is particularly evident in endometrial cancer, in which multiple genes are silenced through hypermethylation. In this review, we discuss the field of epigenetics and relevant techniques to characterize methylation and acetylation alterations. The CpG island methylator phenotype, epimutations and the effects of aging on methylation are also discussed. In endometrial cancer there is evidence that hypermethylation of relevant genes can be reversed using epigenetic inhibitors, resulting in re-expression of silenced genes. Preliminary data also suggest that a panel of methylation biomarkers could be useful for diagnosis and even screening in selected populations at high risk. This disease is particularly well suited for such a strategy given that the endometrium is readily accessible for testing and endometrial cancer precursors are well defined.",
keywords = "Biomarker, Cancer diagnosis, Cancer treatment, DNA methylation, Endometrial cancer, Epigenetics, Intravaginal tampons",
author = "Jiang, {Shi Wen} and Jinping Li and Karl Podratz and Dowdy, {Sean Christopher}",
year = "2008",
month = "9",
doi = "10.1586/14737159.8.5.607",
language = "English (US)",
volume = "8",
pages = "607--616",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Application of DNA methylation biomarkers for endometrial cancer management

AU - Jiang, Shi Wen

AU - Li, Jinping

AU - Podratz, Karl

AU - Dowdy, Sean Christopher

PY - 2008/9

Y1 - 2008/9

N2 - It has become clear that aberrant gene expression, via alterations in promoter methylation or histone acetylation, is a contributing factor for carcinogenesis, perhaps as important as genetic mutation. This is particularly evident in endometrial cancer, in which multiple genes are silenced through hypermethylation. In this review, we discuss the field of epigenetics and relevant techniques to characterize methylation and acetylation alterations. The CpG island methylator phenotype, epimutations and the effects of aging on methylation are also discussed. In endometrial cancer there is evidence that hypermethylation of relevant genes can be reversed using epigenetic inhibitors, resulting in re-expression of silenced genes. Preliminary data also suggest that a panel of methylation biomarkers could be useful for diagnosis and even screening in selected populations at high risk. This disease is particularly well suited for such a strategy given that the endometrium is readily accessible for testing and endometrial cancer precursors are well defined.

AB - It has become clear that aberrant gene expression, via alterations in promoter methylation or histone acetylation, is a contributing factor for carcinogenesis, perhaps as important as genetic mutation. This is particularly evident in endometrial cancer, in which multiple genes are silenced through hypermethylation. In this review, we discuss the field of epigenetics and relevant techniques to characterize methylation and acetylation alterations. The CpG island methylator phenotype, epimutations and the effects of aging on methylation are also discussed. In endometrial cancer there is evidence that hypermethylation of relevant genes can be reversed using epigenetic inhibitors, resulting in re-expression of silenced genes. Preliminary data also suggest that a panel of methylation biomarkers could be useful for diagnosis and even screening in selected populations at high risk. This disease is particularly well suited for such a strategy given that the endometrium is readily accessible for testing and endometrial cancer precursors are well defined.

KW - Biomarker

KW - Cancer diagnosis

KW - Cancer treatment

KW - DNA methylation

KW - Endometrial cancer

KW - Epigenetics

KW - Intravaginal tampons

UR - http://www.scopus.com/inward/record.url?scp=51849124647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849124647&partnerID=8YFLogxK

U2 - 10.1586/14737159.8.5.607

DO - 10.1586/14737159.8.5.607

M3 - Article

VL - 8

SP - 607

EP - 616

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 5

ER -